The innovative antibody, XmAb 5592, presents a distinct mechanism of action targeting interleukin-17A with exceptional potency. Beyond conventional antibodies, it functions as a dual modulator, engaging to simultaneously the target and a regulatory domain, leading to suppression of IL17A product